Soroka University Medical Center, part of the Clalit Health Services Group, is the general hospital of Beersheba, Israel, it serves as the central hospital of the region and provides medical services to approximately one million residents of the South, from Kiryat Gat and Ashkelon to Eilat.

There are 1,173 beds in Soroka Medical Center.

During the past decade, Soroka Medical Center conducted 246 clinical trials. In the 10-year time frame, 246 clinical trials started and 104 clinical trials were completed, i.e. on average, 42.3% percent of trials that started reached the finish line to date. In the past 5 years, 110 clinical trials started and 70 clinical trials were completed. i.e. 63.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Soroka Medical Center" #1 sponsor was "Soroka University Medical Center" with 78 trials, followed by "Eli Lilly and Company" with 19 trials sponsored, "Hoffmann-La Roche" with 19 trials sponsored, "Celgene" with 9 trials sponsored and "Gilead Sciences" with 9 trials sponsored. Other sponsors include 271 different institutions and companies that sponsored additional 170 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Soroka Medical Center" #1 collaborator was "Soroka University Medical Center" with 9 trials as a collaborator, "Ben-Gurion University of the Negev" with 8 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 5 trials as a collaborator, "Merck Sharp & Dohme LLC" with 5 trials as a collaborator and "Eli Lilly and Company" with 4 trials as a collaborator. Other collaborators include 135 different institutions and companies that were collaborators in the rest 120 trials.

According to Clinical.Site data, the most researched conditions in "Soroka Medical Center" are "Crohn's Disease" (9 trials), "Carcinoma, Non-Small-Cell Lung" (8 trials), "Ulcerative Colitis" (8 trials), "Type 1 Diabetes Mellitus" (7 trials) and "Type 2 Diabetes Mellitus" (7 trials). Many other conditions were trialed in "Soroka Medical Center" in a lesser frequency.

Most popular intervention types in "Soroka Medical Center" are "Drug" (263 trials), "Device" (47 trials), "Other" (38 trials), "Biological" (24 trials) and "Procedure" (17 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (87 trials), "Pembrolizumab" (14 trials), "Rituximab" (11 trials), "Carboplatin" (10 trials) and "Pemetrexed" (10 trials). Other intervention names were less common.

The vast majority of trials in "Soroka Medical Center" are 378 trials for "All" genders, 21 trials for "Female" genders and 11 trials for "Male" genders.

Currently, there are 120 active trials in "Soroka Medical Center". 4 are not yet recruiting, 68 are recruiting, 46 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 180 completed trials in Soroka Medical Center, 1 suspended trials, and 44 terminated clinical trials to date.

Out of the total trials that were conducted in Soroka Medical Center, 15 "Phase 1" clinical trials were conducted, 95 "Phase 2" clinical trials and 179 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 70 trials that are defined as “Not Applicable".

Soroka Medical Center has several departments that took part in Clinical trials: "Soroka Medical Center; Oncology Dept" - 10 trials